Qiming Venture Partners Earns Five Spots on 2025 Forbes China Midas List
Identify and recognize 100 investors who have delivered strong performance over the past five years.
Recently, the 2025 Forbes China Midas List was unveiled. For the 19th consecutive year, Forbes China conducted independent research on venture capital investors active in the Chinese mainland market, identifying 100 investors with strong track records over the past five years from nearly a thousand candidates nominated by hundreds of VC firms.
Duane Kuang, Founding Managing Partner; William Hu and Alex Zhou, Managing Partners; Kan Chen, Partner and Co-Head of Healthcare; and Neil Yip, Partner of Qiming Venture Partners, were named to the list.
Duane Kuang, Founding Managing Partner of Qiming Venture Partners
William Hu, Managing Partner of Qiming Venture Partners
Alex Zhou, Managing Partner of Qiming Venture Partners
Kan Chen, Partner and Co-Head of Healthcare Innovation at Qiming Venture Partners
Neil Yip, Partner of Qiming Venture Partners
Named to
The 2025 Forbes China Midas List
Selection Criteria
· 2025 Forbes China Midas List
This is a highly data-driven ranking, combining public data sources with thousands of investment transactions submitted annually by hundreds of investors. To qualify, companies in an investor's portfolio must have gone public or been acquired for at least 1 billion RMB within the past five years, or alternatively, achieved a valuation of at least 6 billion RMB that has at least doubled during the same period. Forbes China places greater weight on realized exits. In terms of evaluation, early-stage investors who achieve high return multiples on projects, or growth-stage investors who return substantial cash, are both considered valid cases.
Source | Forbes China
Past Coverage
Qiming ESG | Qiming Venture Partners Donates HK$3 Million to Tai Po Wang Fuk Court Relief Fund to Support Post-Disaster Reconstruction | Bilingual Qiming Perspectives | Duane Kuang: Hong Kong Has Become a Critical International Financing Channel for Hard Tech Companies Qiming Honors | Qiming Venture Partners Wins Three Awards at China Venture Capital Research Institute's 2025 Annual Golden Investment Awards
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming's portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ:HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ:WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), AusperBio, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.